At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 240 enrolled
Drug / intervention
Celecoxib +1 moredrug
Likely dose
Celecoxib 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6-Week, Randomized, Double-Blind, Parallel-Group Study To Evaluate The Symptomatic Effects And Safety Of Celecoxib 200mg QD Compared To Diclofenac 75mg SR QD In Chinese Patients With Ankylosing Spondylitis, With 6-Week Extension Phase Treatment On Celecoxib 400 Mg QD Or Maintaining Double-Blind Phase Therapy
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Sep 30, 2008·Updated Feb 2, 2021
In Brief
A Phase 3 clinical trial evaluating Celecoxib and Diclofenac SR for Ankylosing Spondylitis. Completed, enrolled 240 participants across 5 sites.
Detailed Summary
This is a local, multicenter, randomized, active comparator, double-blind, parallel group study with extension will be conducted to evaluate the efficacy and safety of celecoxib versus diclofenac SR in the treatment of Chinese patients with Ankylosing Spondylitis (AS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartJul 2009
Primary CompletionJun 2010
Study CompletionAug 2010
TodayJul 2026
First PostedSep 30, 2008
Enrollment StartJul 1, 2009
Primary CompletionJun 1, 2010
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.8 years ago
Interventions
Celecoxibdrug
capsule, 200 mg QD, 6-12 weeks
Diclofenac SRdrug
tablet, 75 mg QD,6-12 weeks